Primary hyperoxaluria in a compound heterozygote infant

Juan Mayordomo-Colunga1, Debora Riverol, Eduardo Salido

  • 1Pediatric Nephrology, Department of Pediatrics, Hospital Universitario Central de Asturias & University of Oviedo, Oviedo, Spain. jmcolunga@hotmail.com

Insights

Infantile primary hyperoxaluria type 1 (PH1) is a severe genetic disorder. Early diagnosis and recognition of nephrocalcinosis are crucial for managing this rare condition in infants.

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Pediatric Nephrology

Background:

  • Primary hyperoxaluria type 1 (PH1) is a rare genetic metabolic disorder affecting glyoxylate metabolism in the liver.
  • Infantile presentations of PH1 are uncommon and frequently lead to rapid progression to end-stage renal failure.

Observation:

  • A 4-month-old infant presented with acute renal failure and nephrocalcinosis.
  • Genetic analysis confirmed compound heterozygosity for mutations in the alanine-glyoxylate aminotransferase gene, indicative of PH1.

Findings:

  • The infant's condition deteriorated rapidly, resulting in death.
  • The case highlights the severe prognosis of infantile PH1, especially with compound heterozygous mutations.

Implications:

  • This case underscores the diagnostic significance of nephrocalcinosis and urolithiasis in infantile PH1.
  • Early identification and management strategies are critical for improving outcomes in severe pediatric kidney diseases.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Genetic Lingo01:11

Genetic Lingo

Overview
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...